Pharmaceutical Gelatin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pharmaceutical gelatin market size is expected to grow from USD 1.35 billion in 2025 to USD 1.42 billion in 2026 and is forecast to reach USD 1.85 billion by 2031 at 5.39% CAGR over 2026-2031. This report is Segmented by Source (Porcine Skin Gelatin, Bovine Gelatin, Fish Gelatin, and Others), Application (Hard Capsule Manufacturing, Soft Capsule Manufacturing, Tablet Binding & Coatings, and More), Type (Type A, Type B and Hybrid / Modified), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Pharmaceutical Gelatin Market Trends and Insights

Booming Nutraceutical Soft-Gel Demand

Soaring demand for omega-3, vitamin D and other fat-soluble supplements keeps soft-gel consumption rising faster than traditional hard capsules. Soft-gels deliver higher bioavailability and consumer convenience, so supplement brands in the United States and Germany now specify pharmaceutical-grade gelatin with lower residual moisture and tighter metal limits. Suppliers such as GELITA market tailored grades for omega-3 encapsulation, expanding contract volumes with nutraceutical fillers. Regional regulatory familiarity with animal-derived excipients supports continued dominance of gelatin over synthetic film alternatives. Meanwhile, private-label vitamin lines at large retailers rely on legacy soft-gel equipment, locking in gelatin demand for the medium term.

Growth of Biologics Requiring Gelatin Stabilizers

Biologic therapies, including monoclonal antibodies and viral-vector vaccines, need excipients to protect fragile proteins during freezing, lyophilization and transport. Collagen-derived peptides with ultra-low endotoxin profiles safeguard antigen integrity and offer proven compatibility with fill-finish lines. VacciPro, a GELITA collagen peptide, entered multiple pandemic-response vaccine formulations and is now incorporated in next-generation influenza programs. Premium pricing for such grades is widening supplier margins and prompting investment in purification technology. As biologics outpace conventional small molecules, demand for pharmaceutical-grade gelatin stabilizers should remain resilient well beyond 2030.

Volatility in Porcine Supply Chain and ASF Outbreaks

African swine fever periodically removes 10-30% of regional pig herds, triggering sudden rawhide shortages and 20-40% swings in gelatin input costs. European capsule fillers now dual-source fish and bovine hides to hedge against future shocks, while Malaysian investors are commissioning ASEAN’s first JAKIM-certified halal gelatin complex to guarantee Muslim-friendly supply theedgemalaysia.com. Such diversification increases logistics complexity and working-capital needs for pharmaceutical buyers.

Other drivers and restraints analyzed in the detailed report include:

• CAPEX Expansion by Capsule OEMs in Asia
• Rising Use of Gelatin In 3-D Printed Drug Delivery
• Regulatory Push toward Plant-based Capsules

Segment Analysis

Porcine skin continued to dominate, holding 44.78% of pharmaceutical gelatin market share in 2025, but fish-derived options are climbing at a 6.45% CAGR owing to halal compliance and supply diversification motives. Researchers have improved marine gel strength 25% using furcellaran blends, removing historical barriers to capsule production. The pharmaceutical gelatin market benefits as coastal processors in Vietnam and Norway secure scale contracts with vaccine and nutraceutical firms. Concurrently, ASEAN governments fund halal-audited extraction lines that shorten approval cycles for Middle-East export dossiers. Bone-derived gelatin still faces BSE-related controls, restricting any sizable rebound.

Rising consumer scrutiny of animal welfare and traceability keeps pressure on supply chains. Producers respond with blockchain lot tracking and dedicated fish gelatin lines to avoid cross-contact. As a result, pharmaceutical buyers gain clearer audit trails, yet carry higher qualification costs. Moving forward, the pharmaceutical gelatin market will see marine collagen extend into chewable gummies, topical films and hemostats, reinforcing multi-source risk mitigation strategies.

Complete Report Scope:

• By Source
  • Porcine Skin Gelatin
  • Bovine Gelatin
  • Fish Gelatin
  • Other Sources
• By Application
  • Hard Capsule Manufacturing
  • Soft Capsule Manufacturing
  • Tablet Binding & Coatings
  • Hemostats & Medical Devices
  • Vaccines & Biotechnology
  • Others
• By Type
  • Type A
  • Type B
  • Hybrid / Modified
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

Europe led revenue with 39.42% in 2025 because stringent GMP enforcement and dense CDMO clusters keep regional buyers sourcing locally. Germany and the United Kingdom drive consumption, leveraging advanced biologics pipelines and occupational know-how in collagen extraction. Yet soaring utility prices and impending sustainability mandates raise operating costs, nudging some plants toward solar thermal pre-heaters and biomass boilers to retain margin parity.

Asia-Pacific is the fastest-growing territory, advancing at a 7.72% CAGR. China’s provincial grants let gelatin firms retrofit food-grade lines to pharmaceutical standards within two years. India’s capacity build highlighted by Nitta Gelatin’s USD 24 million multi-phase investment accelerates collagen peptide outputs geared to both domestic ANDA launches, and US-FDA inspected exports. Southeast Asian sites capture halal premiums, making Malaysia a supply nerve center for GCC importers.

North America sustains high per-capita demand on the back of nutraceutical proliferation and sustained biologics R&D. The United States houses several leading soft-gel CMOs, ensuring continuous throughput even as plant-based capsule lobbying intensifies. Canada’s incentive program for biomanufacturing has attracted new collagen hydrolysis pilots, catering to gene-therapy stabilizers. Smaller but expanding markets such as Brazil and Saudi Arabia invest in gelatin-based hemostat lines to localize surgical supply chains, broadening global diversification options within the pharmaceutical gelatin market.

List of Companies Covered in this Report:

• GELITA AG
• Rousselot (Darling Ingredients)
• PB Leiner
• Nitta Gelatin Inc.
• Weishardt
• Italgel S.r.l.
• Funingpu Biotechnology
• India Gelatine & Chemicals
• Trobas Gelatine
• Sterling Pharma Solutions
• Lonza (Capsugel)
• Catalent
• Aenova Group
• Procaps Group
• Captek Softgel Intl.
• Soft Gel Technologies
• EuroCaps Ltd
• Suheung Co. Ltd
• Titan Biotech

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support